<SEC-DOCUMENT>0001683168-20-001127.txt : 20200408
<SEC-HEADER>0001683168-20-001127.hdr.sgml : 20200408
<ACCEPTANCE-DATETIME>20200408080036
ACCESSION NUMBER:		0001683168-20-001127
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20200406
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200408
DATE AS OF CHANGE:		20200408

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PharmaCyte Biotech, Inc.
		CENTRAL INDEX KEY:			0001157075
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				621772151
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-68008
		FILM NUMBER:		20781117

	BUSINESS ADDRESS:	
		STREET 1:		23046 AVENIDA DE LA CARLOTA, SUITE 600
		CITY:			LAGUNA HILLS
		STATE:			CA
		ZIP:			92653
		BUSINESS PHONE:		(917) 595.2850

	MAIL ADDRESS:	
		STREET 1:		23046 AVENIDA DE LA CARLOTA, SUITE 600
		CITY:			LAGUNA HILLS
		STATE:			CA
		ZIP:			92653

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVILEX, INC.
		DATE OF NAME CHANGE:	20090324

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EFOODSAFETY COM INC
		DATE OF NAME CHANGE:	20010808
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>pharmacyte_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><BR>
&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Current Report</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
April 6, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B><U>PHARMACYTE
BIOTECH, INC.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in
its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; text-align: center"><B><U>Nevada</U></B></TD>
    <TD STYLE="width: 34%; text-align: center"><B><U>333-68008</U></B></TD>
    <TD STYLE="width: 33%; text-align: center"><B><U>62-1772151</U></B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(State or other jurisdiction of incorporation)</TD>
    <TD STYLE="text-align: center">(Commission File Number)</TD>
    <TD STYLE="text-align: center">(I.R.S. Employer Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 50%; text-align: center"><B>23046 Avenida de la Carlota, Suite 600</B><BR>
<B>Laguna Hills, CA</B></TD>
    <TD STYLE="vertical-align: bottom; width: 50%; text-align: center"><B>92653</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(Address of Principal Executive Offices)</TD>
    <TD STYLE="text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant's telephone number, including
area code:&nbsp;<B>(917) 595-2850</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>N/A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[_] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[_] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[_] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[_] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section
12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 30%; border-bottom: black 1.5pt solid; text-align: center">Title of each class</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 31%; border-bottom: black 1.5pt solid; text-align: center">Trading Symbol(s)</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 37%; border-bottom: black 1.5pt solid; text-align: center">Name of exchange on which registered</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">N/A</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">N/A</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">N/A</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &sect;230.405) or Rule 12b-2 of the
Securities Exchange Act of 1934 (17 CFR &sect;240.12b-2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company&nbsp;[_]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;[_]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Item 7.01 Regulation FD Disclosure.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 8, 2020, PharmaCyte Biotech, Inc., a Nevada
corporation (&ldquo;Company&rdquo;), published the press release which is furnished hereto as Exhibit 99.1 and is incorporated
herein by reference. The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed &ldquo;filed&rdquo;
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (&ldquo;Exchange Act&rdquo;), or otherwise subject
to the liabilities under that Section and will not be deemed to be incorporated by reference into any filing of the Company under
the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such
a filing.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Item 8.01 Other Events.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective as of  April 2, 2020,
PharmaCyte Biotech, Inc., a Nevada corporation (&ldquo;Company&rdquo;), entered into a License Agreement
(&ldquo;Agreement&rdquo;) with Hai Kang Life Corporation Limited, a corporation organized under the laws of Hong Kong
(&ldquo;Licensor&rdquo;), pursuant to which the Licensor granted to the Company a license to certain technology owned or
controlled by the Licensor related to COVID-19 diagnostic kits (&ldquo;Kits&rdquo;). Pursuant to the Agreement, the Company
may directly (or through a third party) conduct research, use, develop, market, sell, distribute, import and export Products
for human and veterinary uses in North America, the United Kingdom and certain other European cites
(&ldquo;Territory&rdquo;). A &ldquo;Product&rdquo; is defined as any existing Kit of the Licensor or any future Kit derived
from the Licensor&rsquo;s Kits and includes an in vitro diagnostic test that is designed, manufactured and used within a
single laboratory for which the U.S. FDA is not enforcing any premarket review or other regulatory approval requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is required to use its commercially reasonable efforts
to develop and commercialize at least one Product in the Territory. This obligation to develop and commercialize a Product includes,
among other things, the performance of non-clinical and clinical studies of any Product, the preparation, filing and prosecution
of certain regulatory approvals for such Product (including to allow the Company to market and sell the Product and to get the
Product approved for reimbursement). The Licensor is responsible for all aspects of the manufacture and supply of the Products
to be developed and sold under the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the term of the Agreement, the
Company is required to pay a monthly fee to the Licensor in the amount of $6,000, which monthly fee increases to $50,000 once
the first Product receives regulatory approval from the U.S. FDA. In addition, upon the first commercial sale of a Product,
the Company is required to make quarterly royalty payments equal to 10% of Net Sales (as defined in the Agreement) of any
Product sold pursuant to the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Agreement has a perpetual term
but may be terminated: (i) by the Company unilaterally with 120 days prior written notice; (ii) in the event one party
believes the other party to be in breach of the Agreement, by the non-breaching party if the breaching party does not cure
the breach within 60 days after the date the breaching party was given notice of such breach; or (iii) by the Licensee with
the prior written consent of the Licensor (acting in its sole discretion), but such consent is not to be withheld or delayed
if the Licensee wishes to terminate on account of demonstrable safety or efficacy concerns in respect of the Product. The
Agreement also provides for indemnification by the Licensor and the Licensee under certain circumstances set forth in the
Agreement. The Company may not sell a competing COVID-19 diagnostic kit during the term of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company believes it will need to engage
a partner to be able to do the testing necessary to validate the claims made by the Licensor regarding the sensitivity and specificity
of the technology covered by the Agreement, and the technology&rsquo;s potential clinical utility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to the early stage of both this relationship
and the licensed technology, the Company cannot assure that it will be able to successfully: (i) develop such a Product with the
Company&rsquo;s current resources, on a timely basis, or at all; (ii) obtain the necessary regulatory approvals for such Product;
(iii) commercialize any such Product; and (iv) get such Product approved for reimbursement in the U.S. and elsewhere. In addition,
while the Licensor is obligated to manufacture any such Product, the Company cannot assure that the Licensor&rsquo;s manufacture
of any Products will comply with U.S. regulatory requirements or that any health care facility or provider will be willing or able
to use Products manufactured by the Licensor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing summary is qualified in its
entirety by a copy of the Agreement, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein
by reference.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Item 9.01. Financial Statements and Exhibits.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(<I>d) Exhibits</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><B><U>Exhibit No.</U></B></TD>
    <TD STYLE="text-align: justify"><B><U>Description</U></B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%">99.1</TD>
    <TD STYLE="text-align: justify; width: 85%"><A HREF="pharmacyte_ex9901.htm">Press Release dated April 8, 2020.</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>99.2</TD>
    <TD STYLE="text-align: justify"><A HREF="pharmacyte_ex9902.htm">License Agreement, dated as of April 2, 2020, by and between
    the Company and Hai Kang Life Corporation Limited.</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934 the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top">Date: April 8, 2020</TD>
    <TD COLSPAN="2"><B>PHARMACYTE BIOTECH, INC.</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 53%">&nbsp;</TD>
    <TD STYLE="width: 1%">By:&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 46%"><I>/s/ Kenneth L. Waggoner</I></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: black 1pt solid">Kenneth L. Waggoner<BR>
Chief Executive Officer, President and General Counsel</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pharmacyte_ex9901.htm
<DESCRIPTION>PHARMACYTE BIOTPRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 99.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="logo.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PharmaCyte Biotech Enters into License
Agreement for COVID-19 Diagnostic Kits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">LAGUNA HILLS, CA April 8, 2020 (BUSINESS
NEWSWIRE) &ndash; PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for
cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box<SUP>&reg;</SUP>, announced today that
it entered into a License Agreement (Agreement) with Hai Kang Life Corporation Limited, a corporation organized under the laws
of Hong Kong (Hai Kang), pursuant to which Hai Kang granted to the PharmaCyte a license to certain technology owned or controlled
by Hai Kang related to COVID-19 diagnostic kits (Kits). Pursuant to the Agreement, PharmaCyte may directly (or through a third
party) conduct research, use, develop, market, sell, distribute, import and export Products for human and veterinary uses in North
America, the United Kingdom and certain other European cites (Territory). A &ldquo;Product&rdquo; is defined as any existing Kit
of Hai Kang or any future Kit derived from Hai Kang&rsquo;s Kits and includes an in vitro diagnostic test that is designed, manufactured
and used within a single laboratory for which the U.S. FDA is not enforcing any premarket review or other regulatory approval requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PharmaCyte is required to use commercially
reasonable efforts to develop and commercialize at least one Product in the Territory. This obligation to develop and commercialize
a Product includes, among other things, the performance of non-clinical and clinical studies of any Product, the preparation, filing
and prosecution of certain regulatory approvals for such Product (including to allow PharmaCyte to market and sell the Product
and to get the Product approved for reimbursement). Hai Kang is responsible for all aspects of the manufacture and supply of the
Products to be developed and sold under the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the term of the Agreement, PharmaCyte
is required to pay a monthly fee to Hai Kang in the amount of $6,000; this monthly fee increases to $50,000 once the first Product
receives regulatory approval from the U.S. FDA. In addition, upon the first commercial sale of a Product, PharmaCyte is required
to make quarterly royalty payments equal to 10% of Net Sales (as defined in the Agreement) of any Product sold pursuant to the
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Agreement has a perpetual term but
may be terminated: (i) unilaterally by PharmaCyte with 120 days prior written notice; (ii) in the event one party believes the
other party to be in breach of the Agreement by the non-breaching party if the breaching party does not cure the breach within
60 days after the date the breaching party was given notice of such breach; or (iii) by PharmaCyte with the prior written consent
of Hai Kang (acting in its sole discretion), but such consent is not to be withheld or delayed if PharmaCyte wishes to terminate
on account of demonstrable safety or efficacy concerns in respect of the Product. The Agreement also provides for indemnification
by Hai Kang and PharmaCyte under certain circumstances set forth in the Agreement. PharmaCyte may not sell a competing COVID-19
diagnostic kit during the term of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PharmaCyte believes it will need to engage
a partner to be able to do the testing necessary to validate the claims made by Hai Kang regarding the sensitivity and specificity
of the technology covered by the Agreement, and the technology&rsquo;s potential clinical utility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to the early stage of both this relationship
and the licensed technology, PharmaCyte cannot assure that it will be able to successfully: (i) develop such a Product with PharmaCyte&rsquo;s
current resources, on a timely basis, or at all; (ii) obtain the necessary regulatory approvals for such a Product; (iii) commercialize
any such Product; and (iv) get such Product approved for reimbursement in the U.S. and elsewhere. In addition, while Hai Kang is
obligated to manufacture any such Product, PharmaCyte cannot assure that the Hai Kang&rsquo;s manufacture of any Products will
comply with U.S. regulatory requirements or that any health care facility or provider will be willing or able to use Products manufactured
by Hai Kang.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About PharmaCyte Biotech</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PharmaCyte Biotech, Inc. (PharmaCyte) is
a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell
encapsulation technology known as &ldquo;Cell-in-a-Box<SUP>&reg;</SUP>.&rdquo; This technology will be used as a platform upon
which therapies for several types of cancer and diabetes are being developed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PharmaCyte&rsquo;s therapy for cancer involves
encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or &ldquo;cancer-killing&rdquo;
form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient&rsquo;s tumor as close as
possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is
given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated
cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a &ldquo;bio-artificial
liver&rdquo; and activate the chemotherapy drug at the site of the cancer. This &ldquo;targeted chemotherapy&rdquo; has proven
effective and safe to use in past clinical trials and results in little to no treatment related side effects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PharmaCyte&rsquo;s therapy for Type 1 diabetes
and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce
and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is developing the use of genetically
modified liver cells and stem cells, as well as beta islet cells, to treat diabetes. The encapsulation will be done using the Cell-in-a-Box<SUP>&reg;</SUP>
technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a &ldquo;bio-artificial pancreas&rdquo;
for purposes of insulin production.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Safe Harbor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This press release
may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that express
the current beliefs and expectations of the management of PharmaCyte, including statements regarding the viability of the technology
that is the subject to the Hai Kang Agreement, our ability to gain the necessary approvals to market and commercialize Products
under the Agreement, and the timing and commencement of our first Phase 2b clinical trial. Any statements contained herein that
do not describe historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual
results, performance and achievements to differ materially from those discussed in such forward-looking statements. Factors that
could affect our actual results include our ability to raise the necessary capital to fund our operations and to find partners
to supplement our capabilities and resources, as well as such other factors that are included in the periodic reports on Form 10-K
and Form 10-Q that we file with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as
of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, except as otherwise required
by law, whether as a result of new information, future events or otherwise</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">More information
about PharmaCyte can be found at www.PharmaCyte.com<U>.</U> Information may also be obtained by contacting PharmaCyte&rsquo;s Investor
Relations Department.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Gerald W. Crabtree</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investor Relations:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PharmaCyte Biotech, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investor Relations Department</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Telephone: 917.595.2856</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email: Info@PharmaCyte.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>pharmacyte_ex9902.htm
<DESCRIPTION>LICENSE AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 99.2</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>LICENSE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Sans-Serif; font-size: 9pt; color: Red"><B></B></FONT><FONT STYLE="font-size: 10pt">This LICENSE AGREEMENT (this &ldquo;<B>Agreement</B>&rdquo;) is made as of April
2, 2020 (the &ldquo;<B>Effective Date</B>&rdquo;), between PharmaCyte Biotech, Inc., a company organized under the laws of Nevada
and having an address of 23046 Avenida de la Carlota, Suite 600, Laguna Hills, CA 92653 (&ldquo;<B>Licensee</B>&rdquo;) and Hai
Kang Life Corporation Limited, a corporation organized under the laws of Hong Kong and having an address of Units 601 - 605 Biotech
Centre 1 Hong Kong Science Park, Shatin, NT, HK (Company number 0676913) (&ldquo;<B>Licensor</B>&rdquo;). Licensee and Licensor
are referred to in this Agreement individually as a &ldquo;<B>Party</B>&rdquo; and collectively as the &ldquo;<B>Parties</B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>RECITALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, Licensor developed
a proprietary COVID-19 diagnostic kit and owns and/or controls all tangible or intangible know-how, trade secrets, data, information
and any physical, chemical, or biological materials, inventions, or proposals for research or methods of research pertaining to
the COVID-19 diagnostic kit and the development of the COVID-19 diagnostic kit;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, Licensee wishes
to obtain from Licensor an exclusive license to develop and commercialize the COVID-19 diagnostic kit, and Licensee is willing
to grant such a license, all on the terms and conditions set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in
consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which are hereby
acknowledged, Licensee and Licensor hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ARTICLE 1<BR>
DEFINITIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless the context
otherwise requires, the terms in this Agreement with initial letters capitalized, shall have the meanings set forth below, or the
meaning as designated in the indicated places throughout this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.1&#9;</B>&ldquo;<B>Accounting Standards</B>&rdquo;
means internationally recognized accounting principles (including IFRS, U.S. GAAP, and the like), in each case, as generally and
consistently applied by the applicable selling party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.2&#9;</B>&ldquo;<B>Affiliate</B>&rdquo; means, with
respect to a Person, any other Person that now or in the future, directly or indirectly through one or more intermediaries controls,
is controlled by, or is under common control with such Person, as applicable, but only for so long as such other Person continues
to control, be controlled by, or be under common control with such first Person. For the purpose of this definition, &ldquo;control&rdquo;
(including, with correlative meaning, the terms &ldquo;controlled by&rdquo; and &ldquo;under the common control&rdquo;) means (a)
to possess, directly or indirectly, the power to direct the management or policies of a Person, whether through ownership of voting
securities, by contract relating to voting rights or corporate governance, or otherwise, or (b) direct or indirect beneficial ownership
of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in
a particular jurisdiction) of the voting share capital or other equity interest in a Person.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.3&#9;</B>&ldquo;<B>Claims</B>&rdquo; means all Third
Party demands, claims, actions, proceedings and liability (whether criminal or civil, in contract, tort or otherwise) for losses,
damages, reasonable legal costs and other reasonable expenses of any nature.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.4&#9;</B>&ldquo;<B>Commercialize</B>&rdquo;
or &ldquo;<B>Commercialization</B>&rdquo; means all activities directed to marketing, distributing, detailing, offering for sale
or selling a Product (as well as importing and exporting activities in connection therewith), all activities directed to obtaining
Pricing Approvals, and all activities directed to Phase 4 studies.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.5&#9;</B>&ldquo;<B>Commercially Reasonable Efforts</B>&rdquo;
means the use of reasonable, diligent, good faith efforts and resources, as normally used by a pharmaceutical company of similar
size and financial standing for a product discovered or identified internally by such similarly situated company, which product
is at a similar stage in its development or product life and is of similar market potential, taking into account efficacy, safety,
patent and regulatory exclusivity, anticipated or approved labelling, present and future market potential, competitive market conditions,
the profitability of the product in light of pricing and reimbursement issues, and other relevant factors.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.6&#9;</B>&ldquo;<B>Confidential Information</B>&rdquo;
of a Party means all Know-How, unpublished patent applications and other information and data of a financial, commercial, business,
operational or technical nature of such Party that is: (a) disclosed by or on behalf of such Party or any of its Affiliates or
otherwise made available to the other Party or any of its Affiliates, whether made available orally, in writing or in electronic
form; or (b) learned by the other Party pursuant to this Agreement. The terms of this Agreement are the Confidential Information
of both Parties.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.7&#9;</B>&ldquo;<B>Control</B>&rdquo; or &ldquo;<B>Controlled</B>&rdquo;
means, with respect to any Know-How, Patent or other intellectual property rights, that a Party has the legal authority or right
(whether by ownership, license or otherwise) to grant a license, sublicense, access or other right (as applicable) under such Know-How,
Patent, or other intellectual property rights to the other Party on the terms and conditions set forth herein, in each case without
breaching the terms of any agreement with a Third Party, provided, that if a Party or any of its Affiliates is acquired during
the Term, then the intellectual property of the acquiror of such Party or any of its Affiliates shall not be deemed Controlled
by such Party or Affiliate.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.8&#9;</B>&ldquo;<B>Develop</B>&rdquo; or &ldquo;<B>Development</B>&rdquo;
means all development activities for any Product, including all pre-clinical and clinical testing and studies of any Product, distribution
of Product for use in clinical trials (including placebos and comparators), statistical analyses, and the preparation, filing and
prosecution of any Marketing Authorization Application for any Product, as well as all regulatory affairs related to any of the
foregoing.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.9&#9;</B>&ldquo;<B>Dollar</B>&rdquo; means U.S. dollars,
and &ldquo;$&rdquo; shall be interpreted accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.10 </B>&ldquo;<B>EMA</B>&rdquo; means
the European Medicines Agency or any successor entity thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.11 </B>&ldquo;<B>Emergency
Use Authorization</B>&rdquo; means emergency use authorization pursuant to Section 564 of the Federal Food, Drug and Cosmetic Act,
21 U.S.C.A. 301 et. seq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.12 </B>&ldquo;<B>European
Union</B>&rdquo; means the European Union and its member states as of the Effective Date, which are: Austria, Belgium,
Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy,
Latvia, Lithuania, Luxemburg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, and Sweden, and each
of their successors to the extent such successors occupy the same territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.13 </B>&ldquo;<B>FDA</B>&rdquo;
means the United States Food and Drug Administration or any successor entity thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.14 </B>&ldquo;<B>Field</B>&rdquo;
means all human and veterinary uses, including therapeutic, prophylactic and diagnostic uses in all possible indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.15 </B>&ldquo;<B>First
Commercial Sale</B>&rdquo; means, with respect to any Product in any country or jurisdiction in the Territory, the first arm&rsquo;s
length sale of such Product by Licensee, its Affiliates or Sublicensees to a Third Party for distribution, use in such country
or jurisdiction after the Regulatory Approvals have been obtained for such Product in such country or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.16 </B>&ldquo;<B>Force
Majeure Event</B>&rdquo; means an event that is caused by or results from causes beyond the reasonable control of the affected
Party, including embargoes, war, acts of war (whether war be declared or not), acts of terrorism, insurrections, riots, civil commotions,
strikes, lockouts or other labor disturbances, fire, floods, earthquakes or other acts of God, or acts, omissions or delays in
acting by any Government Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.17 </B>&ldquo;<B>Government
Authority</B>&rdquo; means any federal, national, state, provincial or local government, or political subdivision thereof, or any
multinational organization or any authority, agency or commission entitled to exercise any administrative, executive, judicial,
legislative, police, regulatory or taxing authority or power, any court or tribunal (or any department, bureau or division thereof,
or any governmental arbitrator or arbitral body).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.18 </B>&ldquo;<B>Indication</B>&rdquo;
means a separate and distinct disease or medical condition for which a separate Regulatory Approval is required. For clarity, different
subpopulations of a particular human disease or medical condition (including those distinguished by phenotype, genotype, biomarker
or treatment history) shall nevertheless constitute a single Indication, and different lines of therapy for a particular human
disease or medical condition shall nevertheless constitute a single Indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.19 </B>&ldquo;<B>Invention</B>&rdquo;
shall mean any process, method, improvement, composition of matter, article of manufacture, discovery or finding, patentable or
otherwise, that is conceived, invented, or reduced to practice as a result of a Party exercising its rights or carrying out its
obligations under this Agreement, whether directly or via its Affiliates, agents or independent contractors, including all rights,
title and interest in and to the intellectual property rights therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.20 </B>&ldquo;<B>Know-How</B>&rdquo;
means all technical information, know-how and materials, including without limitation, experimental protocols and procedures, analytical
methods and tests, specifications, biological, chemical, pharmacological, toxicological, preclinical, clinical, assay, control,
and other data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.21 </B>&ldquo;<B>Laboratory
Developed Test</B>&rdquo; means an in vitro diagnostic test that is designed, manufactured and used within a single laboratory
for which the FDA is not enforcing any premarket review or other Regulatory Approval requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.22 </B>&ldquo;<B>Law</B>&rdquo;
means any federal, state, local, foreign or multinational law, statute, standard, ordinance, code, rule, regulation, resolution
or promulgation, or any order by any Government Authority, or any license, franchise, permit or similar right granted under any
of the foregoing, or any similar provision having the force or effect of law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.23 </B>&ldquo;<B>Licensed
Know-How</B>&rdquo; means all Know-How that is Controlled by Licensor or its Affiliates as of the Effective Date or during the
term of this Agreement and relates to a Product and/or Product(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.24 </B>&ldquo;<B>Licensed
Patents</B>&rdquo; means all Patents relating to the Product and/or Products in Licensor&rsquo;s possession or Control on the Effective
Date or during the term of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.25 </B>&ldquo;<B>Licensed
Technology</B>&rdquo; means the Licensed Know-How and Licensed Patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.26 </B>&ldquo;<B>Licensee
Patents</B>&rdquo; means all Patents generated by Licensee or its Affiliates or Sublicensees in the course of Development or Commercialization
of a Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.27 </B>&ldquo;<B>MAA</B>&rdquo;
or &ldquo;<B>Marketing Authorization Application</B>&rdquo; means an application to the appropriate Regulatory Authority for approval
to market a Product (but excluding Pricing Approval) in any particular jurisdiction and all amendments and supplements thereto,
including any Emergency Use Authorization filed with the FDA in the U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.28 </B>&ldquo;<B>MHRA</B>&rdquo;
means the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.29 </B>&ldquo;<B>Net
Sales</B>&rdquo; means, with respect to any Product, the gross amount received by Licensee, any of its Affiliates or Sublicensees
for sales or other dispositions of such Product, less the following deductions, each to the extent (i) reasonable, customary, and
consistent with Licensee&rsquo;s business practices, (ii) actually incurred in respect of such Product and not otherwise recovered
or reimbursed to the selling party, and (iii) included in the gross invoiced sales price:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>freight, postage, shipping costs, and other charges, such as insurance, relating to the transportation and delivery of such
Product;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>sales and excise taxes, customs duties, and any other governmental charges imposed upon the sale of such Product;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>discounts and chargebacks actually granted, allowed or incurred in connection with the sale of such Product, provided that
such discounts and chargebacks, to the extent applicable to the Product and one or more other products of Licensee, its Affiliates
or Sublicensees, are not allocated disproportionately to such Products compared to such other products of Licensee, its Affiliates
or Sublicensees;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>allowances or credits actually given to customers in connection with the sale of such Product and not in excess of the selling
price of such Product, in each case on account of rejection, outdating, recalls or return of such Product;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>rebates, reimbursements, fees or similar payments to (i) wholesalers and other distributors, pharmacies and other retailers,
buying groups (including group purchasing organizations), health care insurance carriers, pharmacy benefit management companies,
health maintenance organizations, Government Authorities, or other institutions or health care organizations in connection with
the sale of such Product; or (ii) to patients and other Third Parties arising in connection with any program applicable to such
Product, under which Licensee or its Affiliates or Sublicensees provide to low income, uninsured or other patients the opportunity
to obtain pharmaceutical products at no cost or reduced cost, in each case provided that such rebates, reimbursements, fees or
similar payments, to the extent applicable to the Product and one or more other products of Licensee, its Affiliates or Sublicensees,
are not allocated disproportionately to such Products compared to such other products of Licensee, its Affiliates or Sublicensees;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any other charges, costs, expenses or accruals that are customarily deducted in the determination of &ldquo;net sales&rdquo;
in accordance with the applicable selling party&rsquo;s Accounting Standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the avoidance of
doubt, if a single item falls into more than one of the categories set forth in clauses (a)-(f) above, such item may not be deducted
more than once.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net Sales shall not
include amounts (whether actually existing or deemed to exist for purposes of calculation) for (i) the transfer of Product among
Licensee and its Affiliates and Sublicensees for subsequent re-sale, (ii) Product transferred at cost or for free for use in clinical
trials; or (iii) Product provided at or below cost as samples or for charitable purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.30 </B>&ldquo;<B>North
America</B>&rdquo; means the United States and Canada, and their respective territories and possessions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.31 </B>&ldquo;<B>Patent</B>&rdquo;
means all patents, patent applications, and invention disclosures, including without limitation, any and all continuations, continuations-in-part,
divisions, patents of addition, confirmations, reissues, renewals, extensions, and counterparts thereof, if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.32 </B>&ldquo;<B>Person</B>&rdquo;
means any individual, partnership, limited liability company, firm, corporation, association, trust, unincorporated organization
or other entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.33 </B>&ldquo;<B>Price</B>&rdquo;
means the price per unit of Product set forth in <U>Exhibit A.</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.34 </B>&ldquo;<B>Pricing
Approval</B>&rdquo; means such governmental approval, agreement, determination or decision establishing prices for a Product that
can be charged and/or reimbursed in regulatory jurisdictions where the applicable Government Authorities approve or determine the
price and/or reimbursement of pharmaceutical products and where such approval or determination is necessary for the commercial
sale of such Product in such jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.35 </B>&ldquo;<B>Product</B>&rdquo;
means any COVID-19 diagnostic kits, including a Laboratory Developed Test produced, Developed, Commercialized, submitted for Regulatory
Approval, and/or sold in any jurisdiction in the Territory, including, without limitation any of Licensor&rsquo;s existing COVID-19
diagnostic kits and any future COVID-19 diagnostic kits derived from Licensor&rsquo;s COVID-19 diagnostic kits. Where applicable,
Product shall additionally refer to all rights and related intellectual property rights Patent rights and Know-How related to such
Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.36 </B>&ldquo;<B>Regulatory
Approval</B>&rdquo; means all approvals, including Pricing Approvals and MAAs or Emergency Use Authorizations, that are necessary
for the commercial sale of a Product in a given country or regulatory jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.37 </B>&ldquo;<B>Regulatory
Authority</B>&rdquo; means any applicable Government Authority responsible for granting Regulatory Approvals for Product, including
the FDA, the EMA, the MHRA and any corresponding national or regional regulatory authorities regulating or otherwise exercising
authority with respect to activities contemplated in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.38 </B>&ldquo;<B>Regulatory
Materials</B>&rdquo; means (a) applications for marketing approvals (including all investigational applications, Emergency Use
Authorization applications, premarket notification submissions, premarket approval submissions, material labeling supplements,
Regulatory Authority meeting requests, and core data sheets), registrations, licenses, authorizations, and approvals (including
Regulatory Approvals), (b) correspondence and reports submitted to or received from Regulatory Authorities (including minutes and
official contact reports relating to any communications with any Regulatory Authority) and all supporting documents with respect
thereto, including all regulatory lists, advertising and promotion documents, adverse event files, and complaint files, and (c)
data contained or relied upon in any of the foregoing, in each case ((a), (b), and (c)) relating to a Product in order to Develop,
manufacture, market, sell or otherwise Commercialize a Product in a particular country or jurisdiction. &ldquo;Regulatory Materials&rdquo;
includes any MAA, Emergency Use Authorization, or Regulatory Approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.39 </B>&ldquo;<B>Schengen
Countries</B>&rdquo; means Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland,
Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Monaco, Netherlands, Norway, Poland, Portugal, San Marino, Slovakia,
Slovenia, Spain, Sweden, Switzerland, and Vatican City.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.40 </B>&ldquo;<B>Sublicensee</B>&rdquo;
means a Third Party to which Licensee has granted a sublicense to research, Develop, make, have made, use, import, offer for sale,
sell and otherwise Commercialize Products in the Field in any particular country in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.41 </B>&ldquo;<B>Subsidiary</B>&rdquo;
means, with respect to a Party or a Third Party, any entity that now or in the future, directly or indirectly through one or more
intermediaries is controlled by such Party or Third Party, as applicable, but for only so long as such control exists. As used
in this definition of &ldquo;Subsidiary&rdquo;, &ldquo;control&rdquo; means (a) to possess, directly or indirectly, the power to
direct the management or policies of an entity, whether through ownership of voting securities, by contract relating to voting
rights or corporate governance, or otherwise, or (b) direct or indirect beneficial ownership of more than fifty percent (50%) (or
such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the voting
share capital or other equity interest in such entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.42 </B>&ldquo;<B>Tax</B>&rdquo;
or &ldquo;<B>Taxes</B>&rdquo; means any (a) all federal, provincial, territorial, state, municipal, local, foreign or other
taxes, imposts, rates, levies, assessments and other charges in the nature of a tax (and all interest and penalties thereon
and additions thereto imposed by any Government Authority), including all income, excise, franchise, gains, capital, real
property, goods and services, transfer, value added, gross receipts, windfall profits, severance, ad valorem, personal
property, production, sales, use, license, stamp, documentary stamp, mortgage recording, employment, payroll, social
security, unemployment, disability, escheat, estimated or withholding taxes, and all customs and import duties, together with
all interest, penalties and additions thereto imposed with respect to such amounts, in each case whether disputed or not; (b)
any liability for the payment of any amounts of the type described in clause (a) as a result of being or having been a member
of an affiliated, consolidated, combined or unitary group; and (c) any liability for the payment of any amounts as a result
of being party to any tax sharing agreement or arrangement or as a result of any express or implied obligation to indemnify
any other person with respect to the payment of any amounts of the type described in clause (a) or (b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.43 </B>&ldquo;<B>Territory</B>&rdquo;
means North America, the Schengen Countries, the United Kingdom, Turkey, and such other countries, if any, as may be agreed upon
by the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.44 </B>&ldquo;<B>Third
Party</B>&rdquo; means any Person other than a Party or an Affiliate of a Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.45 </B>&ldquo;<B>United
States</B>&rdquo; or &ldquo;<B>U.S.</B>&rdquo; means the United States of America including its territories and possessions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.46 </B>&ldquo;<B>Valid
Claim</B>&rdquo; means, with respect to any country, a claim of an issued and unexpired Patent (as may be extended through supplementary
protection certificate or patent term extension or the like) that has not been cancelled, revoked, held invalid or unenforceable
by a decision of a patent office or other Government Authority of competent jurisdiction from which no appeal can be taken (or
from which no appeal was taken within the allowable time period) and which claim has not been disclaimed, denied or admitted to
be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.47 Additional
Definitions. </B>The following table identifies the location of definitions set forth in various Sections of the Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="text-align: justify; width: 70%; border: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Definition</B></FONT></TD>
    <TD STYLE="text-align: justify; width: 30%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Section</B></FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Additional Third Party License</FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">4.2(c)</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Agreement</FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">PREAMBLE</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Bankruptcy Code</FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">7.2(c)</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Disclosing Party</FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">6.1(a)</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Effective Date</FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">PREAMBLE</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Excluded Claim</FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">10.7(j)</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Licensor</FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">PREAMBLE</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Licensor Indemnitees</FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">9.2</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">ICC</FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">10.7(e)</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Indemnified Party</FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">9.3</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Indemnifying Party</FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">9.3</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Infringement</FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">5.4(a)</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Joint Inventions</FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">5.1</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Joint Patents</FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">5.1</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Licensee</FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">PREAMBLE</FONT></TD></TR>
</TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="text-align: justify; width: 70%; border: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Definition</B></FONT></TD>
    <TD STYLE="text-align: justify; width: 30%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Section</B></FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Licensee Indemnitees</FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">9.1</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Notice of Dispute</FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">10.7(a)</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Parties</FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">PREAMBLE</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Party</FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">PREAMBLE</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Receiving Party</FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">6.1(a)</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Royalty Term</FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">4.2(b)</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Sole Inventions</FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">5.1</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Term</FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">7.1</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">Transfer Tax</FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">4.5(c)</FONT></TD></TR>
</TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0"><B>1.48 Interpretation. </B>In this Agreement, unless otherwise
specified:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;includes&rdquo; and &ldquo;including&rdquo; shall mean respectively includes and including without limitation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>words denoting the singular shall include the plural and vice versa and words denoting any gender shall include all genders;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>words such as &ldquo;herein&rdquo;, &ldquo;hereof&rdquo;, and &ldquo;hereunder&rdquo; refer to this Agreement as a whole
and not merely to the particular provision in which such words appear; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Exhibit and other attachments form part of the operative provision of this Agreement and references to this Agreement
shall include references to the Exhibit and attachments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ARTICLE 2<BR>
LICENSES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>2.1&#9;License
Grant. </B>Subject to the terms and conditions of this Agreement, Licensor hereby grants to Licensee an exclusive (even as to
Licensor), royalty-bearing and sublicenseable (including through multiple tiers in accordance with Section 2.2 (<I>Sublicense</I>))
license under the Licensed Technology to, directly or through a third party, conduct research, use, Develop, offer for sale, sell,
market, distribute, import, export, and otherwise Commercialize Products in the Field in the Territory, and to make, have made,
conduct research, and Develop Products in the Field both inside and outside the Territory for Commercialization, sale, and distribution
in the Territory.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>2.2&#9;Sublicense.</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licensee
shall have the right to grant sublicenses under the Licensed Technology; provided that (i) the terms of such sublicense shall be
no less restrictive than those set out in this Agreement; and (ii) Licensee shall remain responsible for any obligations that have
been sublicensed to any Affiliate or Sublicensee and shall be responsible for any acts and omissions of its Affiliates and Sublicensees
that would constitute a breach of Licensee&rsquo;s obligations under this Agreement if they were Licensee&rsquo;s own acts or omissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>2.3&#9;No Implied Licenses; Negative Covenant. </B>Except
as expressly set forth herein, neither Party shall acquire any license or other right or interest, by implication or otherwise,
under any Know-How, Patents, trademarks, copyrights, other intellectual property of the other Party. Licensee shall not, and shall
not permit any of its Affiliates or Sublicensees to, practice any Licensed Technology outside the scope of the license granted
to it under this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>2.4&#9;Exclusivity. </B>Licensor will not, directly or
through a third party, Develop, use, manufacture, offer for sale, sell, market, distribute, import or otherwise Commercialize any
product that is a competing product to any Product(s) in the Field in the Territory during the Term.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ARTICLE 3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>DEVELOPMENT AND COMMERCIALIZATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>3.1&#9;General. </B>Subject to the terms and conditions
of this Agreement, as between the Parties, Licensee shall be solely responsible for the Development and Commercialization of Products
throughout the Territory, including (a) the performance of non-clinical and clinical studies on Products, (b) preparation and submission
of Regulatory Materials for Products, and (c) marketing, promotion, distribution and sale of the Product. As between the Parties,
Licensee shall bear all of the costs and expenses incurred in connection with the Development and Commercialization of Products
in the Territory after the Effective Date.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>3.2&#9;Technology Transfer. </B>With
ten (10) calendar days of the Effective Date, Licensor shall disclose to Licensee all Know-How, including scientific or technical
information related to the Product(s), all pre-clinical, clinical, and/or regulatory documentation, data, information, or reports
related to the Product(s), and all information related to the manufacture of the Product(s) and finished form of the Product(s),
that is reasonably necessary or useful for Licensee to Develop or Commercialize the Product(s) in the Territory. Any additional
Know-How developed or acquired by Licensor during the term of the Agreement shall be promptly disclosed to Licensee. Licensor
shall make all relevant documentation and embodiments of the Know-How Controlled by Licensor available to Licensee through electronic
delivery via a mutually agreeable secure transmission method.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>3.3&#9;Technical Assistance</B>. After completion of
the technology transfer pursuant to Section 3.2 (<I>Technology Transfer</I>), Licensor shall use reasonable endeavors to provide
Licensee with reasonable technical assistance regarding the Development of the Product, as reasonably requested by Licensee. For
the avoidance of doubt, such assistance shall (unless agreed otherwise by the parties) be provided via electronic communication
including, without limitation, telephone, video conference, and email.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>3.4&#9;Diligence</B>. Licensee shall use Commercially
Reasonable Efforts to Develop and Commercialize at least one (1) Product in the Territory. Failure to use Commercially Reasonable
Efforts shall constitute a breach of Licensee&rsquo;s material obligations hereunder, and Licensor may, at its sole discretion,
terminate this Agreement pursuant to Section 7.2(a) (<I>Termination for Material Breach</I>).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>3.5&#9;Regulatory</B>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Licensor shall and hereby does assign to Licensee all of Licensor&rsquo;s entire right, title and interest in any Regulatory
Materials Controlled by Licensor as of the Effective Date and any right, title, and interest in any Regulatory Materials that become
Controlled by Licensor after the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>During the Term, Licensee will be solely responsible for, at its own cost and expense (except as provided herein), all regulatory
matters related to the Development and Commercialization of Product in the Territory, including, without limitation, taking full
responsibility for preparing and filing the relevant Regulatory Materials with the Regulatory Authorities and any recall of the
Product. Licensee shall own all such Regulatory Materials. For the avoidance of doubt, the Parties acknowledge and agree that Licensor
shall have no liability whatsoever in respect of any regulatory activities connected to any Product anywhere in the Territory that
occur after the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>3.6&#9;Manufacturing and Supply</B>.
As between the Parties, Licensor shall be solely responsible for all aspects of the manufacturing and supply of Products for Development
and Commercialization in the Territory.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>3.7&#9;Reporting. </B>Licensee shall keep Licensor reasonably
informed in writing as to the progress and results of its and its Affiliates&rsquo; and Sublicensees&rsquo; Development and Commercialization
of Products under this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Within thirty (30) days after each December 31<SUP>st</SUP> and each June 30<SUP>th</SUP> during the Term prior to the First
Commercial Sale of a Product in any country in the Territory, Licensee shall provide Licensor with a reasonably detailed written
report that sets forth (i) a summary and timeline for all ongoing non-clinical studies and clinical studies for the Product, (ii)
a summary of all material and substantive interactions with applicable Regulatory Authorities during the prior six (6)-month period
with respect to the Product in the Territory, and (iii) updates on key milestones achieved in the prior six (6)-month period or
anticipated to be achieved in the next six (6) months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If, based on the report provided by Licensee, Licensor reasonably believes that further detailed discussions between the
Parties are required, Licensor shall promptly notify Licensee, and the Parties shall hold a meeting, no later than ninety (90)
days following Licensor&rsquo;s receipt of the applicable report, at a mutually agreed time to discuss the Development and Commercialization
of Products, either by telephone or video conference, or if mutually agreed, face-to-face.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>3.8&#9;Subcontractors. </B>Licensee and its Affiliates
and Sublicensees shall have the right to engage subcontractors to Develop and Commercialize Products under this Agreement, provided
that any such subcontractor is bound by written obligations of confidentiality and non-use consistent with this Agreement and Licensee
shall remain responsible for any obligations that have been delegated or subcontracted to any subcontractor and shall be responsible
for any acts and omissions of its and its Sublicensee&rsquo;s subcontractors that would constitute a breach of Licensee&rsquo;s
obligations under this Agreement if they were Licensee&rsquo;s own acts or omissions.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>3.9&#9;Compliance. </B>Each Party covenants
that in performing its obligations or exercising its rights under this Agreement: (a) it shall comply with all applicable Laws,
industry guidance and codes of practice; and (b) it shall not employ or engage any Person who has been debarred or disqualified
by any Regulatory Authority or, to its knowledge, is the subject of debarment or disqualification proceedings by any Regulatory
Authority.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ARTICLE 4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FINANCIAL PROVISIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>4.1&#9;Minimum Purchase Requirements. </B>In each calendar
month during the Term, Licensee shall purchase from Licensor Product in a Dollar amount no less than the amounts specified in the
table below:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD COLSPAN="2" STYLE="border-top: black 1pt solid; text-align: center; vertical-align: top; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Time Period</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Minimum Purchase</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify; text-indent: 0in; width: 3%"><FONT STYLE="font-size: 10pt">1.<FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT>&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 71%"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">From the Effective Date through the calendar month upon which Regulatory Approval from the FDA for the first Product is received</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify; width: 26%"><FONT STYLE="font-size: 10pt">Six Thousand Dollars <BR>
($6,000) per month</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">2&nbsp;</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">From the calendar month following the month upon which Regulatory Approval from the FDA for the first Product is received through the end of the Term</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">Fifty Thousand Dollars <BR>
($50,000) per month</FONT></TD></TR>
</TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Licensor shall invoice Licensee for each monthly payment set
forth in the table above, and Licensee shall pay to Licensor such amount within ten (10) business days after receiving such invoice.
The price payable by Licensee for the Product(s) shall be the Price. Failure to make such payments when due shall be subject to
Section 4.4 (<I>Late Payments</I>).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Royalty Payments.</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Royalty Rate. </B>Subject to the other terms of this Section 4.2 (<I>Royalty Payments</I>), Licensee shall make quarterly
royalty payments to Licensor on a country-by-country basis, on Net Sales of Products sold by Licensee, its Affiliates and Sublicensees
in each country of the Territory, in an amount equal to ten percent (10%) of Net Sales in such country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Royalty Term. </B>Licensee&rsquo;s obligation to pay royalties pursuant to this Section 4.2 (<I>Royalty Payments</I>) shall
commence upon the First Commercial Sale and shall continue, on a country-by-country and Product-by-Product basis, until the termination
of this Agreement (the &ldquo;<B>Royalty Term</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Royalty
Reduction. </B>If Licensee, in its sole discretion, determines that any Third Party intellectual property rights are required
in order to avoid infringement of such Third Party intellectual property rights in connection with the Development or
Commercialization of a Product in the Field in any given jurisdiction within the Territory, then Licensee may negotiate and
obtain a license under, or otherwise pay amounts with respect to any litigation or alternative dispute resolution regarding,
such Third Party&rsquo;s intellectual property rights (each such Third Party license or payment referred to herein as an
&ldquo;<B>Additional Third Party License</B>&rdquo;). Any royalty amounts otherwise payable to Licensor under this Agreement
with respect to Net Sales of any Product by Licensee, its Affiliates or Sublicensees in such jurisdiction will be offset by
the amounts payable to Third Parties pursuant to any Additional Third Party Licenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Royalty
Reports and Payment. </B>Within thirty (30) days after each calendar quarter, commencing with the calendar quarter during which
the First Commercial Sale of a Product is made anywhere in the Territory, Licensee shall provide Licensor with a report showing
(i) gross sales and Net Sales of Product by Licensee in the Territory and (ii) the amount of any royalties due to Licensor. Promptly
after the delivery of the applicable quarterly report, Licensor shall invoice Licensee all royalties owed with respect to Net Sales
for such calendar quarter, and Licensee shall pay Licensor such royalties within ten (10) business days after receiving such invoice.
Failure to make such payments when due shall be subject to Section 4.4 (<I>Late Payments</I>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>4.3&#9;Currency; Exchange Rate. </B>All payments to be
made by Licensee to Licensor under this Agreement shall be made in Dollars by bank wire transfer in immediately available funds
to a bank account designated by written notice from Licensor. The rate of exchange to be used in computing the amount of currency
equivalent in Dollars shall be the foreign exchange rate as of the invoice date provided by the Federal Reserve Bank of New York
(https://apps.newyorkfed.org/markets/autorates/fxrates/external/home) using the 12 Noon Buying Rates provided.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>4.4&#9;Late Payments. </B>If Licensor
does not receive payment of any undisputed sum due to it on or before the fifteenth (15th) calendar day following the due date
therefor, and Licensee fails to cure such non-payment within thirty (30) days of receiving notice of such non-payment from Licensor,
then such non-payment shall constitute a breach of Licensee&rsquo;s material obligations hereunder, and Licensor may, at its sole
discretion, terminate this Agreement pursuant to Section 7.2(a) (<I>Termination for Material Breach</I>).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>4.5&#9;Taxes.</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Taxes on Income. </B>Except as expressly provided in this Section 4.5 (<I>Taxes</I>), each Party shall solely bear and pay
all Taxes imposed on its share of income or gain arising directly or indirectly from the activities of the Parties under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Tax
Cooperation. </B>The Parties agree to cooperate with one another and use Commercially Reasonable Efforts to avoid or reduce,
to the extent permitted by applicable Laws, tax withholding or similar obligations in connection with royalties, milestone
payments, and other payments made by Licensee to Licensor under this Agreement. To the extent Licensee is required by
applicable Law to deduct or withhold Taxes on any payment to Licensor, Licensee shall (i) deduct or withhold such Taxes from
the payment made to Licensor, (ii) promptly notify Licensor of such requirement, (iii) pay to the relevant authorities the
full amount required to be deducted or withheld, and (iv) forward to Licensor an official receipt or other evidence of such
payment and other reasonable documentation evidencing such payment reasonably requested by Licensor. To the extent that
amounts are so withheld and paid to the proper taxing authority, such amounts shall be treated for all purposes of this
Agreement as having been paid to the persons with respect to whom such amounts were withheld. Licensor shall provide Licensee
with any Tax forms that may be reasonably necessary in order for Licensee to not withhold Tax or to withhold Tax at a reduced
rate under an applicable bilateral income tax treaty. Licensor shall use Commercially Reasonable Efforts to provide any such
Tax forms to Licensee at least forty-five (45) days prior to the due date for any payment for which Licensor desires that
Licensee apply a reduced withholding rate. Each Party shall provide the other with reasonable assistance to enable the
recovery, as permitted by applicable Laws, of withholding Taxes or similar obligations resulting from payments made under
this Agreement, such recovery to be for the benefit of Licensor as the Party bearing such withholding Tax under this Section
4.5(b) (<I>Tax Cooperation</I>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Transfer
Tax</B>. Subject to Section 4.5(a) (<I>Taxes on Income</I>), Licensee, on the one hand, and Licensor, on the other hand, shall
each bear and pay fifty percent (50%) of any transfer, stamp, value added, sales, use, or similar Taxes or obligations (&ldquo;<B>Transfer
Tax</B>&rdquo;) imposed on any transaction contemplated under this Agreement. Each Party shall cooperate with the other to file
any Tax returns (as required to be filed under applicable Law) with respect to such Transfer Taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>4.6&#9;Financial Records and Audit. </B>Licensee shall
maintain complete and accurate records in sufficient detail to permit Licensor to confirm the accuracy of royalty payments under
this Agreement. Upon reasonable prior notice, such records shall be open for examination during regular business hours for a period
beginning on the Effective Date until five (5) years from the termination or expiry of this Agreement, at Licensor&rsquo;s expense,
not more often than once each calendar year, by an independent certified public accounting firm selected by Licensor, and for the
sole purpose of verifying the accuracy of the royalty reports furnished by Licensee under this Agreement or any royalty payments
made, or required to be made, by Licensee under this Agreement. Any such accounting firm shall not disclose Licensee&rsquo;s Confidential
Information to Licensor, except to the extent such disclosure is necessary to verify the accuracy of the royalty reports furnished
by Licensee or the royalty payments under this Agreement. If such audit reveals any underpayment, Licensee shall pay such amount
within thirty (30) days after the date of the accountant&rsquo;s report. If such audit reveals any overpayment, such amount shall
be creditable against future royalty payments due under this Agreement (or promptly refunded to Licensee, if there is no future
royalty payment due). Licensor shall bear the full cost of such audit unless such audit reveals an underpayment by Licensee of
more than five percent (5%) of the amount actually due for the audited time period, in which case Licensee shall reimburse Licensor
for the costs for such audit.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ARTICLE 5</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>INTELLECTUAL PROPERTY RIGHTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>5.1&#9;Ownership
of Inventions. </B>Each Party shall solely own any Inventions made solely by it and/or its Affiliates&rsquo; employees,
agents, or independent contractors (&ldquo;<B>Sole Inventions</B>&rdquo;). The Parties shall jointly own any Inventions that
are made jointly by employees, agents, or independent contractors of one Party and its Affiliates together with by employees,
agents, or independent contractors of the other Party and its Affiliates (&ldquo;<B>Joint Inventions</B>&rdquo;). For
clarity, the determination of which Party &ldquo;made&rdquo; a particular Invention shall be made, with respect to patentable
Inventions, in accordance with the rules of inventorship under applicable patent laws. All Patents claiming patentable Joint
Inventions shall be referred to herein as &ldquo;<B>Joint Patents</B>.&rdquo; Except to the extent either Party is restricted
by the licenses granted to the other Party under this Agreement, each Party shall be entitled to practice, license, assign
and otherwise exploit the Joint Inventions and Joint Patents without the duty of accounting to or seeking consent from the
other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>5.2&#9;Disclosure of Inventions</B>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each Party shall promptly disclose to the other Party all Joint Inventions, including any invention disclosures, or other
similar documents, submitted to it by its employees, agents or independent contractors describing such Joint Inventions, and shall
promptly respond to any reasonable request from the other Party for additional information relating to such Joint Inventions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Promptly following the provision of the report in Section 4.2(d) (<I>Royalty Reports and Payment</I>), Licensee shall disclose
to Licensor all Sole Inventions (including any invention disclosures, or other similar documents, submitted to it by its employees,
agents or independent contractors describing such Sole Inventions) made by it and/or its Affiliates in the preceding quarter and
shall promptly respond to any reasonable request from Licensor for additional information relating to such Sole Inventions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>5.3&#9;Patent Prosecution.</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Licensed Patents
and Joint Patents.</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Licensee shall have the first right to, and shall, in its sole discretion with regard to each Licensed Patent, Joint Patent,
or invention disclosure, file, prosecute and maintain such Licensed Patents and Joint Patents in the Territory, at Licensee&rsquo;s
own cost and expense. For the purpose of this Article 5 (<I>Intellectual Property Rights</I>), &ldquo;prosecution&rdquo; shall
include any post-grant proceeding including patent interference proceeding, opposition proceeding and reexamination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Licensee shall consult with Licensor and keep Licensor reasonably informed of the status of the Licensed Patents and Joint
Patents in the Territory and shall promptly provide Licensor with all material correspondence received from any Government Authority
in connection therewith. In addition, Licensee shall use reasonable endeavors to provide Licensor with drafts of all proposed material
filings and correspondence to any Government Authority with respect to the Licensed Patents and Joint Patents in the Territory
for Licensor&rsquo;s review and comment prior to the submission of such proposed filings and correspondences. Licensee shall confer
with Licensor and consider in good faith Licensor&rsquo;s comments prior to submitting such filings and correspondences, but, for
the avoidance of doubt, shall decide (in its absolute discretion) whether to adopt any of Licensor&rsquo;s comments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Licensee
shall notify Licensor of any decision to cease prosecution and/or maintenance of, or not to continue to pay the expenses of
prosecution and/or maintenance of, any Licensed Patents or Joint Patents in the Territory at least forty-five (45) days prior
to any filing or payment due date, or any other due date that requires action, in connection with such Licensed Patent or
Joint Patent. If Licensee makes such a decision to cease prosecution and/or maintenance of, or not to continue to pay the
expenses of prosecution and/or maintenance of, any Licensed Patents or Joint Patents in the Territory, Licensee shall permit
Licensor, at its discretion and at its sole expense, to continue prosecution or maintenance of such Licensed Patent or Joint
Patent. Licensor&rsquo;s prosecution or maintenance of such Licensed Patent or Joint Patent shall not change the
Parties&rsquo; respective rights and obligations under this Agreement with respect to such Licensed Patent or Joint Patent
other than those expressly set forth in this Section 5.3(a)(iii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Licensee Patents. </B>Licensee shall have the sole right to file, prosecute and maintain the Licensee Patents in any jurisdiction
worldwide, at Licensee&rsquo;s cost and expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Cooperation in Prosecution</B>. Each Party shall provide the other Party all reasonable assistance and cooperation in the
patent prosecution efforts provided above in this Section 5.3 (<I>Patent Prosecution</I>), including providing any necessary powers
of attorney and executing any other required documents or instruments for such prosecution and requiring their respective personnel,
agents, consultants, contractors, and other representatives to cooperate with the preparation of and execute any </FONT>documents,
instruments, affidavits, assignments, declarations, and applications reasonably required by the other Party<FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patent Enforcement.</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notification. </B>Each Party shall promptly notify the other party if it becomes aware of any alleged or threatened infringement
by a Third Party of any of the Licensed Patents (&ldquo;<B>Infringement</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Enforcement Right. </B>Licensee shall have the first right to bring and control any legal action in connection with any
Infringement in the Territory at its own expense and as it reasonably determines appropriate. If Licensee decides not to enforce
the Licensed Patents against such Infringement or does not bring such legal action or otherwise take commercially reasonable action
to abate such Infringement before the earlier of: (i) one hundred eighty (180) days after the notice provided pursuant to Section
5.4(a) (<I>Notification</I>), or (ii) ten (10) business days before the time limit (if any) set forth in applicable Law for the
filing of such legal action (provided that notice of infringement has been provided pursuant to Section 5.4(a) (<I>Notification</I>)
prior to such time limit), then Licensor shall have the right to bring and control any legal action in connection with such Infringement
in the Territory at its own expense as it reasonably determines appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Cooperation. </B>At the request and expense of the Party bringing the action under Section 5.4(b) (<I>Enforcement Right</I>)
above, the other Party shall provide reasonable assistance in connection therewith, including by executing reasonably appropriate
documents, cooperating in discovery and joining as a plaintiff party to the action if required by applicable Law to pursue such
action. In connection with any such proceeding, the enforcing Party shall keep the other Party reasonably informed of the status
and progress of such enforcement action, and shall reasonably consider the other Party&rsquo;s comment on any such efforts. The
non-enforcing Party shall be entitled to separate representation in such matter by counsel of its own choice and at its own expense,
but such Party shall at all times cooperate fully with the enforcing Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Expense
and Recoveries. </B>The enforcing Party shall be solely responsible for the cost and expenses incurred in connection with the
enforcement action under Section 5.4(b) (<I>Enforcement Right</I>). If such Party recovers monetary damages from any Third
Party in such enforcement action brought against an Infringement, such recovery shall be allocated first to the reimbursement
of any expenses incurred by the Parties in such enforcement action, and any remaining amounts shall be retained by the
enforcing Party, provided that, if Licensee is the enforcing Party, such remaining amounts shall be included in the Net Sales
subject to the royalty payment by Licensee to Licensor under Section 4.2 (<I>Royalty Payments</I>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ARTICLE 6</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONFIDENTIALITY; PUBLICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>6.1&#9;Duty of Confidence. </B>Subject to the other provisions
of this Article 6</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(<I>Confidentiality; Publication</I>):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>all Confidential Information disclosed by a Party (the &ldquo;<B>Disclosing Party</B>&rdquo;) or its Affiliates under this
Agreement shall be maintained in confidence and otherwise safeguarded by the recipient Party (the &ldquo;<B>Receiving Party</B>&rdquo;),
in the same manner and with the same protection as such Receiving Party maintains its own confidential information;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Receiving Party may only use any such Confidential Information for the purposes of performing its obligations or exercising
its rights under this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Receiving Party may disclose Confidential Information of the other Party to: (i) its Affiliates and sublicensees; and
(ii) employees, directors, agents, contractors, consultants and advisers of the Receiving Party and its Affiliates and sublicensees,
(iii) to such Party&rsquo;s directors, attorneys, independent accountants or financial advisors for the sole purpose of enabling
such directors, attorneys, independent accountants or financial advisors to provide advice to such Party, in each case to the extent
reasonably necessary for the purposes of, and for those matters undertaken pursuant to, this Agreement; provided that such Persons
are bound to maintain the confidentiality of, and non-use obligations in respect of, the Confidential Information in a manner consistent
with the confidentiality provisions of this Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Receiving Party may disclose Confidential Information of the other Party to actual or potential investors, acquirers,
collaborators, licensees, sublicensees and other financial or commercial partners solely for the purpose of evaluating or carrying
out an actual or potential investment, acquisition, collaboration or licensing or sublicensing arrangement in connection with the
Receiving Party; provided that such Persons are bound to maintain the confidentiality of, and non-use obligations in respect of,
the Confidential Information in a manner consistent with the confidentiality provisions of this Agreement, provided that the duration
may be shorter if consistent with applicable industry norms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>6.2&#9;Exceptions. </B>The foregoing obligations in Section
6.1 (<I>Duty of Confidence</I>) shall not apply to the extent that the Receiving Party can demonstrate that such Confidential Information:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>is known by the Receiving Party at the time of its receipt without an obligation of confidentiality, and not through a prior
disclosure by the Disclosing Party, as documented by the Receiving Party&rsquo;s business records;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>is in the public domain before its receipt from the Disclosing Party, or thereafter enters the public domain through no
fault of the Receiving Party;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>is subsequently disclosed to the Receiving Party by a Third Party who may lawfully do so and is not under an obligation
of confidentiality to the Disclosing Party; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>is developed by the Receiving Party independently and without use of, or reference to, any Confidential Information received
from the Disclosing Party, as documented by the Receiving Party&rsquo;s business records.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any combination of features or disclosures
shall not be deemed to fall within the foregoing exclusions merely because individual features are published or available to the
general public or in the rightful possession of the Receiving Party unless the combination itself and principle of operation are
published or available to the general public or in the rightful possession of the Receiving Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>6.3&#9;Authorized Disclosures. </B>Notwithstanding the
obligations set forth in Section 6.1 (<I>Duty of Confidence</I>), a Party may disclose the other Party&rsquo;s Confidential Information
to the extent such disclosure is required by Law, judicial or administrative process, <U>provided</U> that in such event the Receiving
Party shall promptly inform the Disclosing Party of such required disclosure and provide the Disclosing Party an opportunity to
challenge or limit the disclosure obligations. Confidential Information that is disclosed pursuant to this Section 6.3 (<I>Authorized
Disclosures</I>) shall remain otherwise subject to the confidentiality and non-use provisions of this Article 6 (<I>Confidentiality;
Publication</I>), and the Receiving Party disclosing Confidential Information pursuant to Law or court order shall take all steps
reasonably necessary, including seeking of confidential treatment or a protective order to ensure the continued confidential treatment
of such Confidential Information.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>6.4&#9;Data Publication.
</B>Licensor shall not publish nor otherwise publicly disclose any data or results regarding any Product without the prior written
consent of Licensee; provided, however, that Licensor may publish the data and results that it generates solely through the exercise
of their retained right. If Licensee wishes to publish peer reviewed manuscripts disclosing any non-public results of studies
carried out under this Agreement, it shall provide Licensor with the opportunity to review and comment on any proposed publication
which relates to the Product at least thirty (30) days prior to its intended submission for publication. Licensee shall: (i) consider
in good faith any comments thereto provided by Licensor within such thirty (30) day period; and (ii) remove any Confidential Information
of Licensor identified by Licensor as part of its review.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>6.5&#9;Press Release and Use of Names. </B>Each Party
shall have the right to use the other Party&rsquo;s name and logo in presentations, the company&rsquo;s website, collateral materials,
corporate overviews and other public disclosures contemplated by Sections 6.3 (<I>Authorized Disclosures</I>), in each case only
to describe the licensing relationship. Any other use by a Party of the other Party&rsquo;s name and logo shall be subject to such
other Party&rsquo;s prior written consent.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ARTICLE 7</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TERM AND TERMINATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>7.1&#9;Term. </B>The term of this Agreement shall commence
upon the Effective Date and shall remain in effect until terminated pursuant to this Article 7 (<I>Term and Termination</I>) (the
&ldquo;<B>Term</B>&rdquo;).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>7.2&#9;Termination.</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Termination for Material Breach. </B>If either Party believes that the other is in breach of its material obligations hereunder,
then the non-breaching Party may deliver notice of such breach to the other Party, and the allegedly breaching Party shall have
sixty (60) days from such notice to dispute or cure such breach. If the allegedly breaching Party fails to cure, or fails to dispute,
that breach within such time period, then the Party originally delivering the notice of breach may terminate this Agreement effective
on written notice of termination to the other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Termination by Licensee with Licensor&rsquo;s Consent. </B>In addition, Licensee may also terminate this Agreement with
the prior written consent of Licensor (acting in its sole discretion), but such consent not to be withheld or delayed if Licensee
wishes to terminate on account of demonstrable safety or efficacy concerns in respect of the Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Termination for Insolvency. </B>Either Party may immediately terminate this Agreement at any time upon written notice to
the other Party if: (i) such other Party admits in writing that is it unable to pay its debts when due or (being a company) is
deemed unable to pay its debts within the meaning of section 123 of the Insolvency Act 1986; (ii) a petition is filed, a resolution
is passed, or an order is made, for or in connection with the winding-up of such other Party other than for the sole purpose of
a scheme for a solvent amalgamation of such Party with one or more other companies or the solvent reconstruction of that Party,
if not dismissed, bonded or stayed within forty-five (45) days, to the extent applicable; or (iii) an application is made to court,
or an order is made, for the appointment of an administrator, or if an administrator is appointed over such other Party, if not
dismissed, bonded or stayed within forty-five (45) days, to the extent applicable; or (iv) any event occurs, or proceeding is taken,
with respect to such other Party in any jurisdiction to which it is subject that has an effect equivalent or similar to any of
the events mentioned in this Section 7.2(c) (<I>Termination for Insolvency</I>). All rights and licenses granted under or pursuant
to this Agreement by each Party to the other Party, as applicable, are and shall otherwise be deemed to be, for purposes of Section
365(n) of the Title 11, United States Code, as amended (the &ldquo;<B>Bankruptcy Code</B>&rdquo;), licenses of rights to &ldquo;intellectual
property&rdquo; as defined under Article 101(35A) of the Bankruptcy Code. The Parties agree that Licensee, as a licensee of such
intellectual property rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the
Bankruptcy Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Unilateral Termination by Licensee. </B>Licensee may unilaterally terminate this Agreement for any reason upon a 120-day
written notice to Licensor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>7.3&#9;Effect of Termination.</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the termination
of this Agreement for any reason:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the licenses granted by Licensor to Licensee under the Licensed Technology and all rights relating thereto shall terminate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>all amounts outstanding at the date of termination shall immediately be due and payable to Licensor by Licensee; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each
Party shall promptly return or (at the other Party&rsquo;s election) destroy and irretrievably erase all embodiments of the other
Party&rsquo;s Confidential Information which are in its power, possession, custody or control; provided, that each Party may retain
one copy of such Confidential Information for the sole purpose of performing any continuing obligations hereunder or for archival
purposes and shall continue to comply with the terms of Article 6 (<I>Confidentiality; Publication</I>) in respect of the same.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>7.4&#9;Survival. </B>Expiration or
termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or termination.
Without limiting the foregoing, the provisions of Articles 1 (<I>Definitions</I>), 9 (<I>Indemnification; Liability; Insurance</I>)
and 10 (<I>General Provisions</I>), and Sections 4.5 (<I>Late Payments</I>), 4.7 (<I>Financial Records and Audit</I>), 5.1 (<I>Ownership
of Inventions</I>), 5.3(b) (<I>Joint Patents</I>), 5.3(c) (<I>Licensee Patents</I>), 5.3(d) (<I>Cooperation in Prosecution</I>),
6.1 (<I>Duty of Confidence</I>), 6.2 (<I>Exceptions</I>), 6.3 (<I>Authorized Disclosures</I>), 7.1 (<I>Term</I>), 7.3 (<I>Effect
of Termination</I>), 7.4 (<I>Survival</I>) and 7.5 (<I>Termination Not Sole Remedy</I>) shall survive the expiration or termination
of this Agreement for any reason.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>7.5&#9;Termination Not Sole Remedy. </B>Termination is
not the sole remedy under this Agreement and, whether or not termination is effected and notwithstanding anything contained in
this Agreement to the contrary, all other remedies shall remain available except as agreed to otherwise herein.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ARTICLE 8</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REPRESENTATIONS AND WARRANTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>8.1&#9;Representations and Warranties of Each Party.
</B>Each Party represents and warrants to the other Party as of the Effective Date that:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>it has the full right, power and authority to enter into this Agreement, to perform its obligations hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>this Agreement has been duly executed by it and is legally binding upon it, enforceable in accordance with its terms, and
does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be
bound, nor violate any material law or regulation of any court, governmental body or administrative or other agency having jurisdiction
over it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>8.2&#9;Representations and Warranties by Licensor. </B>Licensor
represents and warrants to Licensee as of the Effective Date that:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Title; Encumbrances</B>.
Licensor solely owns the entire right, title and interest in and to the Licensed Technology, free and clear from any mortgages,
pledges, liens, security interests, conditional and installment sale agreement, encumbrances, charges or claim of any kind, and
it has the right to grant the licenses to Licensee as purported to be granted pursuant to this Agreement, and Licensor has not
previously granted any license or rights under the Licensed Technology that is inconsistent with the license granted to Licensee
hereunder;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Notice
of Infringement</B>. In the three (3) years prior to the Effective Date, Licensor has not received any written notice from any
Third Party asserting or alleging that any research or development of any Product by or on behalf of Licensor prior to the Effective
Date infringed or misappropriated the intellectual property rights of such Third Party;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Non-Infringement</B>.
To Licensor&rsquo;s knowledge, the Development and Commercialization of any Product can be carried out in the manner reasonably
contemplated as of the Effective Date in each jurisdiction in the Territory without infringing any Valid Claim granted to a Third
Party;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>No
Debarment.</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the course of developing Products before the Effective Date, Licensor has not used any employee, consultant or contractor
who (a) has been debarred by any Regulatory Authority in the United States, the European Union or China, (b) to Licensor&rsquo;s
knowledge, has been debarred by any Regulatory Authority outside the United States, the European Union and China or (c) to Licensor&rsquo;s
knowledge, is the subject of a debarment proceeding by any Regulatory Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Neither Licensor nor any of its Affiliates, nor any of its or their respective officers, employees, or agents has made an
untrue statement of material fact or fraudulent statement to the FDA or any other Regulatory Authority with respect to the Development
of the Product, failed to disclose a material fact required to be disclosed to the FDA or any other Regulatory Authority with respect
to the Development of the Product, or committed an act, made a statement, or failed to make a statement with respect to the Development
of the Product that could reasonably be expected to provide a basis for the FDA to invoke its policy respecting &ldquo;Fraud, Untrue
Statements of Material Facts, Bribery, and Illegal Gratuities&rdquo;, set forth in 56 Fed. Reg. 46191 (September 10, 1991) and
any amendments thereto or any analogous laws or policies in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Licensor and its Affiliates (a) have complied and shall comply with all applicable Law governing bribery, money laundering,
and other corrupt practices and behavior (including, as applicable, the U.S. Foreign Corrupt Practices Act and UK Bribery Act)
and (b) shall not, directly or indirectly, offer, give, pay, promise to pay, or authorize the payment of any bribes, kickbacks,
influence payments, or other unlawful or improper inducements to any Person in whatever form (including gifts, travel, entertainment,
contributions, or anything else of value).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>No
Proceeding</B>. There are no pending, and to Licensor&rsquo;s knowledge, no threatened, adverse actions, suits, claims, interferences
or formal governmental investigations involving any Product and/or the Licensed Technology by or against Licensor or any of its
Affiliates in or before any Government Authority;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>No
Licensed Patents</B>. There are no Licensed Patents owned or controlled by Licensor or its Affiliates and neither Licensor
nor any of its Affiliates has filed any Patents on or prior to the Effective Date that (i) contain any claims directed to
inventions within Licensed Know-How or that otherwise claim or describe any Licensed Know-How, or (ii) are necessary for or
would be infringed by the research, use, Development, sale, marketing, distribution, import, export, and/or other
Commercialization of any Product;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(g)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Development and Commercialization of Products. </B>To Licensor&rsquo;s knowledge, there are no Patents, Know-How or other
intellectual property owned by a Third Party and not included in the Licensed Technology that are necessary for the research, use,
Development, sale, marketing, distribution, import, export and/or other Commercialization of any Product; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(h)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Inventory</B>. To Licensor&rsquo;s knowledge, the information provided by Licensor with respect to the inventory of Product
is complete and accurate. All of the Product to be provided under Section 4.1 (<I>Minimum Purchase Requirements</I>) have been
manufactured, handled and stored in accordance with all applicable Laws, including the current Good Manufacturing Practice, Quality
System standards set forth in 21 C.F.R. Part 820, and, as applicable, good clinical laboratory practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>8.3&#9;Full Disclosure. </B>To Licensor&rsquo;s knowledge
as of the Effective Date, Licensor has disclosed to Licensee and made available to Licensee for review (a) all material non-clinical
and clinical reports for the Product, and (b) all other material information (including relevant correspondence with Regulatory
Authorities) relating to the Product, in each of clauses (a) or (b) to the extent such reports or information are reasonably available
to Licensor and pertain to the safety or efficacy of the Product.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.4 Disclaimer.
</B>EXCEPT AS EXPRESSLY STATED IN THIS ARTICLE 8 (<I>REPRESENTATIONS AND WARRANTIES</I>), NO REPRESENTATION, CONDITION OR WARRANTY
WHATSOEVER IS MADE OR GIVEN BY OR ON BEHALF OF LICENSEE OR LICENSOR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ARTICLE 9</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>INDEMNIFICATION; LIABILITY; INSURANCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>9.1&#9;Indemnification by Licensor. </B>Licensor shall
indemnify and hold Licensee, its Affiliates, and their respective officers, directors, agents and employees (&ldquo;<B>Licensee
Indemnitees</B>&rdquo;) harmless from and against any Claims against them arising or resulting from: (a) the negligence or willful
misconduct of any of the Licensor Indemnitees; (b) the breach of this Agreement by Licensor, including any warranties or representations
made by Licensor to Licensee under this Agreement; or (c) the Development, manufacture or Commercialization of any Product by or
on behalf of Licensor or any of its Affiliates or licensees prior to the Effective Date; except in each case, to the extent such
Claims result from the activities set forth in Section 9.2 (<I>Indemnification by Licensee</I>) for which Licensee is obligated
to indemnify Licensor Indemnitees.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>9.2&#9;Indemnification
by Licensee. </B>Licensee shall indemnify and hold Licensor, its Affiliates and their respective trustees, officers,
directors, agents and employees (&ldquo;<B>Licensor Indemnitees</B>&rdquo;) harmless from and against any Claims against them
arising or resulting from: (a) the negligence or willful misconduct of any of the Licensee Indemnitees; (b) the breach of
this Agreement by Licensee, including any warranties or representations made by Licensee to Licensor under this Agreement; or
(c) the Development or Commercialization of any Product by or on behalf of Licensee or any of its Affiliates or sublicensees
after the Effective Date; except in each case, to the extent such Claims result from the activities set forth in Section 9.1
(<I>Indemnification by Licensor</I>) for which Licensor is obligated to indemnify Licensee Indemnitees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>9.3&#9;Indemnification Procedure. </B>If
either Party is seeking indemnification under Sections 9.1 (<I>Indemnification by Licensor</I>) or 9.2 (<I>Indemnification by
Licensee</I>) (the &ldquo;<B>Indemnified Party</B>&rdquo;), it shall inform the other Party (the &ldquo;<B>Indemnifying Party</B>&rdquo;)
of the Claim giving rise to the obligation to indemnify pursuant to such Section as soon as reasonably practicable after receiving
notice of the Claim. The Indemnifying Party shall have the right to assume the defense of any such Claim for which it is obligated
to indemnify the Indemnified Party. The Indemnified Party shall cooperate with the Indemnifying Party and the Indemnifying Party&rsquo;s
insurer as the Indemnifying Party may reasonably request, and at the Indemnifying Party&rsquo;s cost and expense. The Indemnified
Party shall have the right to participate, at its own expense and with counsel of its choice, in the defense of any Claim that
has been assumed by the Indemnifying Party. Neither Party shall have the obligation to indemnify the other Party in connection
with any settlement made without the Indemnifying Party&rsquo;s written consent, which consent shall not be unreasonably withheld
or delayed. If the Parties cannot agree as to the application of Section 9.1 (<I>Indemnification by Licensor</I>) or 9.2 (<I>Indemnification
by Licensee</I>) to any Claim, pending resolution of the dispute pursuant to Section 10.7 (<I>Dispute Resolution</I>), the Parties
may conduct separate defenses of such Claims, with each Party retaining the right to claim indemnification from the other Party
in accordance with Section 9.1 (<I>Indemnification by Licensor</I>) or 9.2 (<I>Indemnification by Licensee</I>) upon resolution
of the underlying Claim.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>9.4&#9;Mitigation of Loss. </B>Each Indemnified Party
shall take and shall procure that its Affiliates take all such reasonable steps and action as are reasonably necessary or as the
Indemnifying Party may reasonably require in order to mitigate any Claims (or potential losses or damages) under this Article 9
(<I>Indemnification; Liability; Insurance</I>). Nothing in this Agreement shall or shall be deemed to relieve any Party of any
common law or other duty to mitigate any losses incurred by it.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>9.5&#9;Limitation of Liability. </B>NEITHER PARTY SHALL
BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES (INCLUDING CONSEQUENTIAL OR INCIDENTAL
LOSS OF PROFIT, LOSS OF OPPORTUNITY OR LOSS OF USE) ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY
NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 9.5 (<I>LIMITATION OF LIABILITY</I>)
IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 9.1 (<I>INDEMNIFICATION
BY LICENSOR</I>) OR 9.2 (<I>INDEMNIFICATION BY LICENSEE</I>), OR DAMAGES AVAILABLE FOR A PARTY&rsquo;S OR BREACH OF CONFIDENTIALITY
OBLIGATIONS IN ARTICLE 6 (<I>CONFIDENTIALITY; PUBLICATION</I>).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>9.6&#9;Insurance. </B>Each
Party shall procure and maintain insurance, including product liability insurance, in each case, in a manner adequate to
cover its obligations hereunder and consistent with normal business practices of prudent companies similarly situated at all
times during which any Product is being clinically tested or commercially distributed or sold by such Party hereunder. The
Parties shall not be permitted to self-insure without the other Party&rsquo;s prior written consent. Each Party shall procure
insurance at its own expense. Such insurance does not create a limit of either Party&rsquo;s liability with respect to its
indemnification obligations under this ARTICLE 11 (<I>Indemnification</I>). Each Party shall provide the other Party with
written evidence of such insurance upon request. Each Party shall provide the other Party with written notice at least thirty
(30) days before the cancellation, non-renewal or material change in such insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ARTICLE 10</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>GENERAL PROVISIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.1 Force Majeure.
</B>Neither Party shall be held liable to the other Party nor be deemed to have defaulted under or breached this Agreement for
failure or delay in performing any obligation under this Agreement to the extent such failure or delay is caused by a Force Majeure
Event. The affected Party shall notify the other Party in writing of such Force Majeure Event as soon as reasonably practical,
and shall promptly undertake and continue diligently all reasonable efforts necessary to cure such Force Majeure Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.2 Assignment.
</B>This Agreement may not be assigned or otherwise transferred, nor may any right or obligation hereunder be assigned or transferred
in whole or part, by either Party without the prior written consent of the other Party. Notwithstanding the foregoing, either Party
may, without consent of the other Party, assign this Agreement and its rights and obligations hereunder: (i) in whole or in part
to an Affiliate of such Party, or (ii) in whole to its successor in interest to all or substantially all of the business of such
Party to which this Agreement relates, whether by merger, sale of stock, sale of assets or other transaction. Any attempted assignment
not in accordance with this Section 10.2 (<I>Assignment</I>) shall be null and void and of no legal effect. Any permitted successor
of a Party or any permitted assignee of all of a Party&rsquo;s rights under this Agreement that has also assumed all of such Party&rsquo;s
obligations hereunder in writing shall, upon any such succession or assignment and assumption, be deemed to be a party to this
Agreement as though named herein in substitution for the assigning Party, whereupon the assigning Party shall cease to be a party
to this Agreement and shall cease to have any rights or obligations under this Agreement. The terms and conditions of this Agreement
shall be binding upon, and shall inure to the benefit of, the Parties and their respective successors and permitted assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.3 Performance
by Affiliates. </B>Each Party may discharge any obligations and exercise any right hereunder through any of its Affiliates. Each
Party hereby guarantees the performance by its Affiliates of such Party&rsquo;s obligations under this Agreement, and shall cause
its Affiliates to comply with the provisions of this Agreement in connection with such performance. Any breach by a Party&rsquo;s
Affiliate of any of such Party&rsquo;s obligations under this Agreement is a breach by such Party, and the other Party may proceed
directly against such Party without any obligation to first proceed against such Party&rsquo;s Affiliate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.4 Severability.
</B>If any one or more of the provisions contained in this Agreement is held invalid, illegal or unenforceable in any respect,
the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired
thereby, unless the absence of the invalidated provision(s) adversely affects the substantive rights of the Parties. The Parties
shall in such an instance use their best efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal
and enforceable provision(s) which, insofar as practical, implement the purposes of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><B>10.5 Notices. </B>All
notices which are required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by facsimile
or email (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally-recognized
overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 80pt; text-align: justify">If to Licensee, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 80pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 120pt; text-align: left">PharmaCyte Biotech, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 120pt; text-align: left">23046 Avenida de la Carlota, Suite 600</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 120pt; text-align: left">Laguna Hills, CA 92653</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 120pt; text-align: left">U.S.A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 120pt; text-align: left">Attn: Kenneth L. Waggoner</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 80pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 80pt; text-align: justify">with copies to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 80pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 120pt; text-align: left">Reed Smith LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 120pt; text-align: left">1901 Avenue of Stars, Suite 700</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 120pt; text-align: left">Los Angeles, CA 90067-6078<BR>
Attn: Michael Sanders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 80pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 80pt; text-align: justify">If to Licensor, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 80pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 120pt; text-align: left">Hai Kang Life Corporation Limited</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 120pt; text-align: left">Units 601 - 605 Biotech Centre</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 120pt; text-align: left">1 Hong Kong Science Park,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 120pt; text-align: left">Shatin, NT, HK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 120pt; text-align: left">Attn: Professor Albert Cheung-Hoi Yu</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">or to such other address(es) as the Party
to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such notice shall be
deemed to have been given: (a) when delivered, if personally delivered or sent by facsimile on a business day (or if delivered
or sent on a non-business day, then on the next business day); (b) on the business day after dispatch, if sent by nationally-recognized
overnight courier; or (c) on the fifth (5th) business day following the date of mailing, if sent by mail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><B>10.6
Governing Law. </B>This Agreement and any dispute or claim arising out of or in connection with it or its subject matter or
formation (including non-contractual disputes or claims) shall be governed by and construed in accordance with the laws of
Hong Kong Special Administrative Region of the People&rsquo;s Republic of China without reference to any rules of conflict of
laws that would require the application of the laws of a different jurisdiction. The terms of this Agreement are intended
solely for the benefit of each Party to this Agreement. Except as otherwise expressly stated in this Agreement, no one other
than a Party to this Agreement may enforce any of its terms under the Contracts (Rights of Third Parties) Ordinance, Cap. 623
of the Laws of Hong Kong. Where any clause of this Agreement entitles any third party to enforce any term of this Agreement
under the Contracts (Rights of Third Parties) Ordinance, the Parties to this Agreement reserve the right to vary that term or
any other term of this Agreement without the consent of that third party. The United Nations Convention on Contracts for the
International Sale of Goods shall not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.7 Dispute Resolution.
</B>If any dispute, controversy or claim arises between the Parties in relation to this Agreement or the breach thereof the Parties
shall follow the following procedures in an attempt to resolve such dispute, controversy or claim:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Party claiming that such a dispute exists shall give notice in writing (&ldquo;<B>Notice of Dispute</B>&rdquo;) to the
other Party of the nature of the dispute;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>within fourteen (14) days of receipt of a Notice of Dispute, designated senior executives of the Parties shall meet in person
and at this meeting they shall use their reasonable endeavors to resolve the dispute (it being understood that (i) the initial
designated senior executives shall be Kenneth Waggoner on behalf of Licensee, and Professor Albert Cheung-Hoi Yu on behalf of Licensor,
and (ii) each Party shall be entitled to name a substitute senior executive to attend such meeting upon written notice to the other
Party, provided that such senior executive is of at least comparable seniority to the executive named herein and has the authority
to resolve such dispute without seeking further approval);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If the designated senior executives are unable to resolve the dispute during the meeting described in (b) above or if for
any reason such meeting does not take place within the period specified in (b) above, then the dispute will be referred to the
Chief Executive Officer of Licensee and the Chief Executive Officer of Licensor who shall meet to discuss and seek to resolve the
issue;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If, within a further period of thirty (30) days, or if in any event within sixty (60) days of initial receipt of the Notice
of Dispute, whichever is shorter, the dispute has not been resolved, or if, for any reason, the meeting of the Chief Executive
Officer of Licensee and the Chief Executive Officer of Licensor described in (c) above has not been held within sixty (60) days
of initial receipt of the Notice of Dispute, then the Parties agree that either Party may initiate binding arbitration proceedings
to resolve the dispute, unless such dispute relates to an Excluded Claim; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the relevant parties shall submit their dispute to binding arbitration administered by the International Chamber of Commerce
(&ldquo;<B>ICC</B>&rdquo;) pursuant to its arbitrations rules then in effect, and judgment on the arbitration award may be entered
in any court having jurisdiction thereof. Each Party hereby expressly and irrevocably waives the right to trial by jury in any
event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>The
arbitration shall be conducted by a panel of three arbitrators qualified in Hong Kong law and having substantial experience
regarding the issues in dispute and the diagnostic/pharmaceutical business: within thirty (30) days after initiation of
arbitration, each Party shall select one person to act as arbitrator and the two Party-selected arbitrators shall select a
third arbitrator within thirty (30) days of their appointment. If the arbitrators selected by the Parties are unable or fail
to agree upon the third arbitrator, the third arbitrator shall be appointed by ICC. The arbitrators may permit discovery
(including depositions) as they deem appropriate in the circumstances of the dispute provided that the extent and scope shall
be proportionate in terms of time and cost. The arbitrators shall have no power to award punitive, special, incidental or
consequential damages. The arbitrator&rsquo;s decision and award shall be final and binding upon all Parties. The place of
arbitration shall be Hong Kong, and all proceedings and communications shall be in English.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.05in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Either Party may apply to the arbitrators for interim injunctive relief until the arbitration award is rendered or the controversy
is otherwise resolved. Either Party also may, without waiving any remedy under this Agreement, seek from any court having jurisdiction
any injunctive or provisional relief necessary to protect the rights or property of that Party pending the arbitration award. Each
Party shall bear its own costs and expenses and attorneys&rsquo; fees and an equal share of the arbitrators&rsquo; fees and any
administrative fees of arbitration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.05in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.05in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except to the extent necessary to confirm an award or as may be required by law, neither a Party nor an arbitrator may disclose
the existence, content, or results of an arbitration without the prior written consent of both Parties. In no event shall an arbitration
be initiated after the date when commencement of a legal or equitable proceeding based on the dispute, controversy or claim would
be barred by the applicable statute of limitations under the applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.05in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.05in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Parties agree that, in the event of a dispute over the nature or quality of performance under this Agreement, neither
Party may terminate this Agreement until final resolution of the dispute through arbitration or other judicial determination. The
Parties further agree that any payments made pursuant to this Agreement pending resolution of the dispute shall be refunded if
an arbitrator or court determines that such payments are not due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.05in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.05in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.05in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.05in"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.05in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.05in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>As used in this Section, the term &ldquo;<B>Excluded Claim</B>&rdquo; shall mean a dispute, controversy or claim that concerns
(a) the scope, validity, enforceability, inventorship or infringement of a patent, patent application, trademark (including service
marks, logos, and other indicia of origin used in commerce) or copyright (including works of authorship whether or not copyrightable),
in each case whether or not registered; or (b) any antitrust, anti-monopoly or competition law or regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.05in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><B>10.8 Entire Agreement;
Amendments. </B>This Agreement, together with the Exhibit hereto, contains the entire understanding of the Parties with respect
to the subject matter hereof. Any other express or implied agreements and understandings, negotiations, writings and commitments,
either oral or written, with respect to the subject matter hereof are superseded by the terms of this Agreement. The Exhibit to
this Agreement is incorporated herein by reference and shall be deemed a part of this Agreement. This Agreement may be amended,
or any term hereof modified, only by a written instrument duly executed by authorized representative(s) of both Parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><B>10.9 Headings.
</B>The captions to the several Articles, Sections and subsections hereof are not a part of this Agreement, but are merely for
convenience to assist in locating and reading the several Articles and Sections hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><B>10.10
Independent Contractors. </B>It is expressly agreed that Licensor and Licensee shall be independent contractors and that the
relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither Licensor nor
Licensee shall have the authority to make any statements, representations or commitments of any kind, or to take any action,
which shall be binding on the other Party, without the prior written consent of the other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.11 Waiver. </B>The
waiver by either Party hereto of any right hereunder, or of any failure of the other Party to perform, or of any breach by the
other Party, shall not be deemed a waiver of any other right hereunder or of any other breach by or failure of such other Party
whether of a similar nature or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.12 Cumulative
Remedies. </B>No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and in addition
to any other remedy referred to in this Agreement or otherwise available under law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.13 Waiver of
Rule of Construction. </B>Each Party has had the opportunity to consult with counsel in connection with the review, drafting and
negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against
the drafting Party shall not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.14 Business Day
Requirements. </B>In the event that any notice or other action or omission is required to be taken by a Party under this Agreement
on a day that is not a business day then such notice or other action or omission shall be deemed to be required to be taken on
the next occurring business day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.15 Translations.
</B>This Agreement is in the English language only, which language shall be controlling in all respects, and all versions hereof
in any other language shall be for accommodation only and shall not be binding upon the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.16 Counterparts.
</B>This Agreement may be executed in two or more counterparts by original signature, facsimile or PDF files, each of which shall
be deemed an original, but all of which together shall constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>{REMAINDER OF
PAGE INTENTIONALLY LEFT BLANK</B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.45in 0pt 0; text-indent: 0.45in">IN WITNESS WHEREOF, the Parties
intending to be bound have caused this License Agreement to be executed by their duly authorized representatives as of the Effective
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.45in 0pt 0; text-indent: 0.45in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>PharmaCyte Biotech, Inc.</B></FONT></TD>
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Hai Kang Life Corporation Limited</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">By: /s/Kenneth L. Waggoner</TD>
    <TD STYLE="font-size: 10pt">By: /s/ Albert Cheung-Hoi Yu</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Name: Kenneth L. Waggoner</TD>
    <TD STYLE="font-size: 10pt">Name: Professor Albert Cheung-Hoi Yu</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Title: CEO, President and General Counsel</TD>
    <TD STYLE="font-size: 10pt">Title: CEO</TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Product
Prices</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="border: black 1pt solid; width: 50%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Product</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; width: 50%; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Price</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 6.25pt"><FONT STYLE="font-size: 10pt">50 sample kit (C02_01_1185_150)</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">11,760 HKD</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 6.25pt"><FONT STYLE="font-size: 10pt">100 sample kit (C02_01_1185_300)</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">21,000 HKD</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  Z 1,# 2(  A$! Q$!_\0
M'    @(# 0$               <&" ,$!0(!_\0 3!   0,# 04% P4)#0D
M     0(#!  %$08'$B$Q40@306%Q%"(R%2.!D:$6%R0W0G2"L<$S0U)68G-U
MDI2RL]'2-#4V5&-RDZ/A_\0 &0$  @,!                  0! @,%_\0
M,A$  @(! P,# @,'!0       0(  Q$2(3$$05$387$RH2.!P044%6*1HO B
M,U*QT?_:  P# 0 "$0,1 #\ :^W"^ZBT;IPWVQW5.[[2AI49^,VM(2H'X5
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6,?VZ8G^YKZ/HYVSG^[5"BBBE8Y/_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
